Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Xenon Pharmaceuticals Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Xenon Pharmaceuticals Inc. is not a good value stock. Xenon Pharmaceuticals Inc. is not a good growth stock. Xenon Pharmaceuticals Inc. is not very popular among insiders. Xenon Pharmaceuticals Inc. is a mediocre stock to choose.
Log in to see more information.
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives...

News

Xenon Pharmaceuticals showcases azetukalner data at EEC
Xenon Pharmaceuticals showcases azetukalner data at EEC

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Globe Newswire Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE...\n more…

Candriam S.C.A. Has $20.35 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Candriam S.C.A. Has $20.35 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Ticker Report Candriam S.C.A. decreased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.0% during the 2nd quarter, according to the company in its most recent disclosure with the...\n more…

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

Ticker Report Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading on Wednesday. Stock investors bought 4,063 put options on the stock. This represents an increase of...\n more…

Xenon Pharmaceuticals (NASDAQ:XENE) Given "Outperform" Rating at Royal Bank of Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Given "Outperform" Rating at Royal Bank of Canada

Ticker Report Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)s stock had its "outperform" rating reiterated by analysts at Royal Bank of Canada in a note issued to investors on Tuesday, Benzinga...\n more…

Brokerages Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $58.78
Brokerages Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $58.78

Ticker Report Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been assigned an average rating of "Buy" from the nine ratings firms that are presently covering the stock, MarketBeat...\n more…